Get the Stockscreener App
11.27
3.18%
-0.37
After Hours:
11.32
0.05
+0.44%
Satellos Bioscience Inc stock is traded at $11.27, with a volume of 62,334.
It is down -3.18% in the last 24 hours and up +0.00% over the past month.
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.
See More
Previous Close:
$11.64
Open:
$11.69
24h Volume:
62,334
Relative Volume:
15.12
Market Cap:
$232.47M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$11.20
$11.98
1-Week Range:
$10.72
$11.98
52-Week Range:
$10.72
$11.98
Satellos Bioscience Inc Stock (MSLE) Company Profile
Name
Satellos Bioscience Inc
Sector
Industry
Phone
-
Address
-
Compare MSLE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MSLE
Satellos Bioscience Inc
|
11.27 | 240.10M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Satellos Bioscience Inc Stock (MSLE) Latest News
Satellos Bioscience Inc. - Baystreet.ca
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy - Investing News Network
Satellos Bioscience Doses First Patient in Phase 2 Pediatric Duchenne Study of SAT-3247 - TipRanks
Satellos Bioscience Completes US$57.2 Million Cross-Border Public Offering and Nasdaq Listing - Global Legal Chronicle
This Canadian biotech stock is undervalued, analyst says - Cantech Letter
Satellos price target raised to $40 from $5 at Oppenheimer - Yahoo Finance
Satellos Closes US$57.2 Million Public Offering in Canada and the United States - 富途牛牛
Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - PharmiWeb.com
Satellos Bioscience to Highlight Muscle-Regeneration Platform at Guggenheim Biotech Summit 2026 - TipRanks
Stream Satellos Guggenheim biotech summit fireside chat live online - Stock Titan
Satellos Bioscience Raises US$57.2 Million in Cross-Border Equity Offering to Advance Muscle Disease Pipeline - TipRanks
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares - BioSpace
Latham Advises on Satellos’ US$50 Million Initial US Offering - Legal Desire Media and Insights
Satellos Bioscience raises $57.2 million in public offering By Investing.com - Investing.com Canada
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise - pharmiweb.com
Satellos Bioscience Completes $57.2 Million Public Offering - marketscreener.com
Satellos Bioscience raises $57.2 million in public offering - Investing.com
Satellos Brief: Closes US$57.2M Public Offer in Canada and United States, Including Exercise of Underwriters' Option to Purchase Additional Shares - marketscreener.com
(MSCL) Equity Market Report (MSCL:CA) - Stock Traders Daily
Satellos prices $50M public offering - MSN
Satellos Raises US$50 Million in Cross-Border Offering as Shares Debut on Nasdaq - TipRanks
Satellos Brief: Announcing Pricing of US$50 Million Public Offering in Canada and the United States - marketscreener.com
Satellos Bioscience prices $50 million public offering - Investing.com
Satellos Bioscience prices $50 million public offering By Investing.com - Investing.com UK
Canadian Investment Regulatory Organization Trading HaltMSCL - marketscreener.com
Satellos announces pricing of US$50 million public offering in Canada and the United States - marketscreener.com
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States - marketscreener.com
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Applicati - pharmiweb.com
Satellos announces launch of public offering in Canada and the United States and filing of application to list on Nasdaq - marketscreener.com
Satellos launches public offering, applies for Nasdaq listing - MSN
Satellos Plans Cross-Border Share Offering and Nasdaq Listing to Fund Muscle Disease Pipeline - TipRanks
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq - marketscreener.com
(MSCL) Advanced Trading Insights (MSCL:CA) - Stock Traders Daily
(MSCL) Strategic Equity Report (MSCL:CA) - Stock Traders Daily
Satellos appoints Antoinette Paone as chief development officer and head of Regulatory Affairs - marketscreener.com
Satellos appoints Antoinette Paone as chief development officer By Investing.com - Investing.com Australia
Satellos Bioscience Taps Antoinette Paone as Chief Development Officer - Contract Pharma
Satellos Strengthens Executive Bench With Veteran Regulator as Duchenne Program Advances - TipRanks
Satellos Biosciences Brief: Appointing Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs - marketscreener.com
Satellos Bioscience Welcomes New Chief Development Officer - GuruFocus
(MSCL) Technical Pivots with Risk Controls (MSCL:CA) - Stock Traders Daily
Satellos Bioscience Brief: Announcing Share Consolidation in Connection with Proposed Nasdaq Listing - marketscreener.com
Satellos Bioscience Consolidates Shares in Push for Nasdaq Listing - 富途牛牛
(MSCL) Advanced Equity Analysis (MSCL:CA) - Stock Traders Daily
(MSCL) Technical Data (MSCL:CA) - Stock Traders Daily
(MSCL) Stock Analysis and Trading Signals (MSCL:CA) - Stock Traders Daily
Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy - BioSpace
Satellos receives FDA clearance for phase 2 Duchenne trial - Investing.com
Satellos Tackles Duchenne ‘As Stem Cell People Solving a Stem Cell Problem’ - Citeline News & Insights
Satellos to Participate in December Investor Conferences - Business Wire
Does DMD start in the womb? New research challenges old beliefs. - Muscular Dystrophy News
Satellos Bioscience Inc Stock (MSLE) Financials Data
There is no financial data for Satellos Bioscience Inc (MSLE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):